Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Sandoz Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (682)
Cancellation by sponsor (321)
Prescription medicine registration (54)
Section 14, TGO91 consent (17)
Cancellation or suspension (8)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)

Date

2024 (82)
2023 (78)
2022 (67)
2021 (121)
2020 (153)
2019 (53)
2018 (60)
2017 (50)
2016 (4)
2015 (39)
2014 (20)
2013 (24)
2012 (13)
2011 (51)
2010 (47)
2009 (37)
2008 (27)
2007 (21)
2006 (21)
2005 (54)
2004 (12)
2003 (10)
2002 (10)
2001 (6)
2000 (5)
1999 (5)
1998 (9)
1997 (4)
1991 (3)

Results for "[search-keyword]"

Search

Sponsor content

1087 result(s) found, displaying 491 to 500

OXYLIEVE MR oxycodone hydrochloride 5 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXYLIEVE MR oxycodone hydrochloride 20 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXYLIEVE MR oxycodone hydrochloride 40 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXYLIEVE MR oxycodone hydrochloride10 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXYLIEVE MR oxycodone hydrochloride 80 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
VALACICLOVIR SZ valaciclovir (as hydrochloride) 1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROSUVASTATIN SZ rosuvastatin (as calcium) 5 mg film-coated tablets bottle Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROSUVASTATIN SZ rosuvastatin (as calcium) 10 mg film-coated tablets bottle Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROSUVASTATIN SZ rosuvastatin (as calcium) 20 mg film-coated tablets bottle Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROSUVASTATIN SZ rosuvastatin (as calcium) 40 mg film-coated tablets bottle Cancelled under Section 30(1)(c) of the Act

26 June 2020

Cancellation by sponsor

Requested by Sandoz Pty Ltd

Pages

First page
Previous page
…
Page 46
Page 47
Page 48
Page 49
Current page 50
Page 51
Page 52
Page 53
Page 54
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.